Inhibition of Cholecystokinin-Stimulated Pancreaticobiliary Output in Man by the Cholecystokinin Receptor Antagonist MK-329

References

• Cantor P. Cholecystokinin in plasma. Digestion 1989; 42: 181–201
   PubMed Web of Science ®Google Scholar
• Beglinger C, Fried M, Whitehouse I, Jansen J B, Lamers C B, Gyr K. Pancreatic enzyme response to a liquid meal and to hormonal stimulation. J Clin Invest 1985; 75: 1471–1476
   PubMed Web of Science ®Google Scholar
• Cantor P, Petronijevic L, Pedersen J F, Worning H. Cholecystokinetic and pancreozymic effect of Osulfated gastrin compared with nonsulfated gastrin and cholecystokinin. Gastroenterology 1986; 91: 1154–1163
   PubMed Web of Science ®Google Scholar
• Liddle R A, Goldfine I D, Rosen M S, Taplitz R A, Williams J A. Cholecystokinin bioactivity in human plasma. J Clin Invest 1985; 75: 1144–1152
   PubMed Web of Science ®Google Scholar
• Zucker K A, Adrian T E, Modlin I M. Cholecystokinin receptor antagonists. J Surg Res 1988; 45: 496–504
   PubMed Web of Science ®Google Scholar
• Makovec F, Bani M, Cereda R, et al. Pharmacologic properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforsch/ Drug Res 1987; 37: 1235–1268
   Google Scholar
• Setnikar I, Bani M, Cereda R, et al. Pharmacological characterization of a new potent and specific nonpolypeptidic cholecystokinin antagonist. Arnzeimittelforsch/Drug Res 1987; 37: 703–707
   PubMed Web of Science ®Google Scholar
• Chang R S L, Lotti V J. Biochemical and pharmacologic characterization of a new extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci USA 1986; 83: 4923–4926
   PubMed Web of Science ®Google Scholar
• Evans B E, Bock M G, Rittle K E, et al. Design of potent, oral, effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc Natl Acad Sci USA 1986; 83: 4918–4922
   PubMed Web of Science ®Google Scholar
• Konturek S I, Tasler J, Konturek J W, et al. Effects of non‐peptidal CCK receptor antagonist (L‐364,718) on pancreatic responses to cholecystokinin, gastrin, bombesin, and meat feeding in dogs. Gut 1989; 30: 110–117
   PubMed Web of Science ®Google Scholar
• Lotti V J, Pendleton R G, Gould R J, Hanson H M, Chang R S L, Clineschmidt B J. In vivo pharmacology of L‐364, 718, a new potent nonpeptide peripheral cholecystokinin antagonist. J Pharmacol Exp Ther 1987; 241: 103–109
   PubMed Web of Science ®Google Scholar
• Pendleton R G, Bendesky R J, Schaffer L, Nolan T E, Gould R J, Clineschmidt B J. Roles of endogenous cholecystokinin in biliary, pancreatic and gastric function: studies with L‐364, 718, a specific cholecystokinin receptor antagonist. J Pharmacol Exp Ther 1987; 241: 210–216
   Google Scholar
• Liddle R A, Gertz B A, Kanyama S, et al. Effects of a novel cholecystokinin receptor antagonist, MK‐329, on gallbladder contraction and gastric emptying in humans: implications for the physiology of CCK. J Clin Invest 1989; 84: 1220–1225
   PubMed Web of Science ®Google Scholar
• Worning H, Müllertz S. pH and pancreatic enzymes in the human duodenum during digestion of a standard meal. Scand J Gastroenterol 1966; 1: 268–283
   PubMedGoogle Scholar
• Cantor P. Evaluation of a radioimmunoassay for cholecystokinin in human plasma. Scand J Clin Lab Invest 1986; 46: 213–221
   PubMed Web of Science ®Google Scholar
• Schaffalitzky de Muckadell O B, Fahrenkrug J. Radioimmunoassay of secretin in human plasma. Scand J Clin Lab Invest 1977; 37: 155–162
   PubMed Web of Science ®Google Scholar
• You C H, Rominger J M, Chey W Y. Potentiation effect of cholecystokinin‐octapeptide on pancreatic bicarbonate secretion stimulated by a physiologic dose of secretin in humans. Gastroenterology 1983; 85: 40–45
   PubMed Web of Science ®Google Scholar
• Grizzle J E. The two period changeover design and its use in clinical trials. Biometrics 1965; 21: 467–481
   PubMed Web of Science ®Google Scholar
• Kerstens P J S M, Tamers C BHW, Jansen J B M J, de Jong A J L, Hessels M, Hafkenscheid J C M. Physiological plasma concentrations of cholecystokinin stimulated pancreatic enzyme secretion and gallbladder contraction in man. Life Sci 1985; 36: 565–569
   PubMed Web of Science ®Google Scholar
• Adelson J W, Miller P E. Heterogeneity of the exocrine pancreas. Am J Physiol 1989; 256: G817–G825
   PubMed Web of Science ®Google Scholar
• Olsen O, Schaffalitzky de Muckadell O B, Cantor P. The significance of plasma CCK and secretin in the oleate stimulated pancreatico‐biliary secretion in man. Int J Pancreatol 1986; 1: 363–372
   PubMedGoogle Scholar
• Anderson L, Dockray G J. The cholecystokinin antagonist L‐364,718 inhibits the action of cholecystokinin but not bombesin on rat pancreatic secretion in vivo. Eur J Pharmacol 1988; 146: 307–311
   PubMedGoogle Scholar
• Hildebrand P, Beglinger C, Gyr K, et al. Effects of cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man. J Clin Invest 1990; 85: 640–646
   PubMed Web of Science ®Google Scholar
• Adler G, Reinshagen M, Koop I, Arnold R, Rovati L. Inhibition of stimulated pancreatic secretion in man by a cholecystokinin antagonist (CR 1505). Digestion 1988; 40: 2A
   Google Scholar
• Meyer B M, Beglinger C, Jansen J B M J, et al. Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet 1989; 2: 12–15
   PubMed Web of Science ®Google Scholar
• Hewson G, Leighton G E, Hill R G, Hughes J. The cholecystokinin receptor antagonist L‐364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin. Br J Pharmacol 1988; 93: 79–84
   PubMedGoogle Scholar
• Green T, Dimaline R, Peikin S, Dockray G J. Action of the cholecystokinin antagonist L‐364,718 on gastric emptying in the rat. Am J Physiol 1988; 255: G685–G689
   Google Scholar
• Gertz B J. Potential clinical applications of a CCK antagonist. Cholecystokinin antagonists, R Y Wang, R Schoenfeld. Alan R. Liss Inc., New York 1988; 327–342
   Google Scholar